pxl-1 Antibody

Basic Research Questions

How to validate pxl-1 antibody specificity in C. elegans models?

• Methodological answer:

  • Perform Western blot analysis using lysates from wild-type and pxl-1 knockout strains (e.g., ok1483 allele). A specific antibody should detect a band at the predicted molecular weight (~70 kDa) in wild-type samples, with no signal in knockouts .

  • Use immunofluorescence to confirm subcellular localization patterns (e.g., dense bodies in body wall muscle, podosome-like structures in pharyngeal muscle) and compare with GFP-tagged PXL-1 fusion proteins .

  • Validate cross-reactivity by testing antibody performance in heterologous systems (e.g., yeast expressing HA-tagged PXL-1) .

What are the optimal conditions for pxl-1 antibody in immunofluorescence?

• Methodological answer:

  • Fix worms with 4% paraformaldehyde and permeabilize with 0.1% Triton X-100.

  • Use a 1:200–1:500 antibody dilution in blocking buffer (1% BSA/PBS).

  • Co-stain with actin markers (e.g., phalloidin) to confirm localization to sarcomeres .

How to interpret pxl-1 localization discrepancies between body wall and pharyngeal muscle?

• Methodological answer:

  • Body wall muscle: PXL-1 localizes to dense bodies and M-lines via LIM domain interactions .

  • Pharyngeal muscle: PXL-1 forms ring-shaped structures near sarcolemmas, indicative of podosome-like adhesions. Use tissue-specific promoters (e.g., myo-2 for pharynx) to validate antibody targeting .

Advanced Research Questions

How to design experiments assessing pxl-1’s role in muscle contraction?

• Methodological answer:

  • Use pxl-1(ok1483) mutants and rescue strains expressing PXL-1 exclusively in pharyngeal muscle .

  • Quantify pharyngeal pumping rates via video microscopy in mutants vs. rescued strains.

  • Combine antibody-based localization studies with calcium imaging to link structural defects to functional impairment .

Resolving contradictions in pxl-1 antibody performance across studies

• Methodological answer:

  • Compare antibody clones: Polyclonal vs. monoclonal antibodies may recognize distinct epitopes (e.g., LIM domains vs. N-terminal regions) .

  • Validate using isoform-specific mutants. For example, PXL-1a (body wall) vs. PXL-1b (pharyngeal epithelial cells) .

  • Standardize fixation protocols to preserve epitopes in different muscle types .

Integrating pxl-1 antibody data with genetic interaction studies

• Methodological answer:

  • Perform yeast two-hybrid screens to identify PXL-1-binding partners (e.g., DEB-1/vinculin, UNC-95) .

  • Use co-immunoprecipitation (IP) with pxl-1 antibody to confirm interactions in vivo .

  • Generate double mutants (e.g., pxl-1; deb-1) and analyze synthetic phenotypes via antibody staining .

Comparative Antibody Performance Table

Key Considerations for Data Interpretation

• Tissue-specific isoforms: PXL-1a (body wall) and PXL-1b (pharyngeal) may require distinct antibody validation workflows .

• Functional redundancy: Paxillin family members (e.g., Hic-5) might compensate in certain tissues, necessitating combinatorial knockdown approaches .

• Epitope accessibility: LIM domain-targeting antibodies are critical for studying mechanotransduction in muscle adhesion complexes .